Organon & Co.
For the period ended Mar 31, 2025. Filed May 2, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 2, 2025
OGN$13.89+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Unaudited, $ in millions)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash Flows from Operating Activities | ||
| Net income | $87 | $201 |
| Adjustments to reconcile net income to net cash flows provided by operating activities: | ||
| Depreciation | 34 | 32 |
| Amortization | 50 | 33 |
| Acquired in-process research and development and milestones | 6 | 15 |
| Fair value changes in contingent consideration | 11 | — |
| Deferred income tax (benefit) expense | (17) | 5 |
| Stock-based compensation | 24 | 26 |
| Unrealized foreign exchange gain | (15) | (18) |
| Other | 20 | 5 |
| Net changes in assets and liabilities, net of assets acquired | ||
| Accounts receivable | (85) | 163 |
| Inventories | 3 | 19 |
| Other current assets | (11) | (57) |
| Trade accounts payable | (149) | (349) |
| Accrued and other current liabilities | 39 | (15) |
| Income taxes payable | 38 | (6) |
| Other | 40 | 22 |
| Net Cash Flows Provided by Operating Activities | 75 | 76 |
| Cash Flows from Investing Activities | ||
| Capital expenditures | (32) | (46) |
| Acquired in-process research and development and milestones | (10) | — |
| Dermavant acquisition, net of cash acquired | (75) | — |
| Purchase of product rights and asset acquisition | (55) | (50) |
| Net Cash Flows Used in Investing Activities | (172) | (96) |
| Cash Flows from Financing Activities | ||
| Proceeds from debt | 90 | — |
| Repayments of debt | (93) | (2) |
| Employee withholding taxes related to stock-based awards | (1) | (2) |
| Dividend payments | (71) | (70) |
| Net Cash Flows Used in Financing Activities | (75) | (74) |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 44 | (24) |
| Net Decrease in Cash and Cash Equivalents | (128) | (118) |
| Cash and Cash Equivalents, Beginning of Period | 675 | 693 |
| Cash and Cash Equivalents, End of Period | $547 | $575 |
-7-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.